SCHEMBL6866882

SCHEMBL6866882

CC(=O)[C@@H](N)CS

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12852246 1.00
SCHEMBL5943374 1.00
Cysteine SCHEMBL21747580 0.78 PTGS1 (0.84)
SCHEMBL17071957 0.78
SCHEMBL16704942 0.78
Cysteine SCHEMBL27613026 0.78 PTGS1 (0.84)
SCHEMBL11891014 0.78
SCHEMBL8583187 0.77
Cysteine SCHEMBL6244297 0.76 PTGS1 (0.80)
Cysteine SCHEMBL1275659 0.76 PTGS1 (0.80)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0041935-B1 N-(VINBLASTINOYL-23) DERIVATIVES OF AMINO ACIDS AND PEPTIDES AND THEIR PREPARATION OMNICHEM Société anonyme (BE) 1984-09-19 EP claimed
US-4388305-A LESS TOXIC THAN VINCRISTINE OR VINDESINE OMNICHEM S.A. (BE) 1983-06-14 US claimed
US-20240067702-A1 LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 US disclosed
US-11746114-B2 Thermally sensitive protecting groups for cysteine for peptide cyclization and selective disulfide bond formation UNIVERSITY OF WINDSOR (CA) 2023-09-05 US disclosed
US-11708513-B2 Pressure sensitive adhesive comprising (meth)acrylic polymer and amino acid crosslinker 3M INNOVATIVE PROPERTIES COMPANY (US) 2023-07-25 US disclosed
EP-3481383-B1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME CELLIX BIO PRIVATE LTD (IN) 2023-06-14 EP disclosed
WO-2023094680-A1 PHOTODYNAMIC THERAPY AND DIAGNOSIS RMW CHO GROUP LIMITED (CN) 2023-06-01 WO disclosed
US-20230144876-A1 IMMUNE INDUCER CONTAINING POLYNUCLEOTIDE-PEPTIDE CONJUGATE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME THE UNIVERSITY OF KITAKYUSHU (JP) 2023-05-11 US disclosed
US-20230045048-A1 IL-15 COMPOSITIONS AND METHODS OF USE THEREOF PROVIVA THERAPEUTICS (HONG KONG) LIMITED (CN) 2023-02-09 US disclosed
WO-2022174179-A9 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2023-02-02 WO disclosed
CN-114746105-A IL-15 compositions and methods of use thereof 普罗维瓦疗法香港有限公司 2022-07-12 CN disclosed
WO-2011017209-A1 USE OF MELANOCORTINS TO TREAT DYSLIPIDEMIA IPSEN PHARMA S.A.S. (FR) 2011-02-10 WO disclosed
US-7785825-B2 Compositions and methods for dehydration and cyclization of peptides, synthetic compounds, and lantibiotics THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2010-08-31 US disclosed
US-20100081786-A1 Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-01 US disclosed
US-20090270457-A1 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. 2009-10-29 US disclosed
US-20090264380-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. 2009-10-22 US disclosed
WO-2009061411-A2 USE MELANOCORTINS TO TREAT INSULIN SENSITIVITY IPSEN PHARMA S.A.S. (FR) 2009-05-14 WO disclosed
US-20090118506-A1 6,11-BRIDGED BIARYL MACROLIDES ENANTA PHARMACEUTICALS, INC. 2009-05-07 US disclosed
US-20070082378-A1 Convergent synthesis of proteins by kinetically controlled ligation UNIVERSITY OF CHICAGO (US) 2007-04-12 US disclosed
US-4388305-A LESS TOXIC THAN VINCRISTINE OR VINDESINE OMNICHEM S.A. (BE) 1983-06-14 US disclosed